A prospective study of vitamin D, proinflammatory cytokines, and risk of fragility fractures in women on aromatase inhibitors for breast cancer-Reference-Cited by-同舟云学术

A prospective study of vitamin D, proinflammatory cytokines, and risk of fragility fractures in women on aromatase inhibitors for breast cancer

Published:2024-07-08 Issue: Volume: Page:
ISSN:0167-6806
Container-title:Breast Cancer Research and Treatment
language:en
Short-container-title:Breast Cancer Res Treat

Author:

Liang Emily,Beshara Michael,Sheng Haiyang,Huang Xin-Wei,Roh Janise M.,Laurent Cecile A.,Lee Catherine,Delmerico Jennifer,Tang Li,Lo Joan C.,Hong Chi-Chen,Ambrosone Christine B.,Kushi Lawrence H.,Kwan Marilyn L.,Yao Song

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s10549-024-07423-6.pdf

Reference44 articles.

1. Nabieva N, Fasching PA (2021) Endocrine treatment for breast cancer patients revisited-history, standard of care, and possibilities of improvement. Cancers (Basel) 13(22):5643

2. Goldvaser H, Barnes TA, Šeruga B et al (2018) Toxicity of extended adjuvant therapy with aromatase inhibitors in early breast cancer: a systematic review and meta-analysis. J Natl Cancer Inst 110(1):31

3. Hadji P, Aapro MS, Body JJ et al (2017) Management of aromatase inhibitor-associated bone loss (aibl) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and SIOG. J Bone Oncol 7:1–12

4. Yao S, Laurent CA, Roh JM et al (2020) Serum bone markers and risk of osteoporosis and fragility fractures in women who received endocrine therapy for breast cancer: a prospective study. Breast Cancer Res Treat 180(1):187–195

5. Pacifici R (1996) Estrogen, cytokines, and pathogenesis of postmenopausal osteoporosis. J Bone Miner Res 11(8):1043–1051